Tratamiento de la fibrosis pulmonar idiopática
Tratamiento de la fibrosis pulmonar idiopática
Issue
Section
Editorial
How to Cite
Tratamiento de la fibrosis pulmonar idiopática.
rev. colomb. neumol. [Internet]. 2016 May 24 [cited 2024 Nov. 23];26(4). Disponible en: https://doi.org/10.30789/rcneumologia.v26.n4.2014.1
Dimensions
license
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Article visits 1123 | PDF visits 1519
Downloads
Download data is not yet available.
- Antoniou K, Margaritopoulos G, Siafakas N. Pharmacologic treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev. 2013;22:218-91.
- Buendia I, Caro M, Curbelo P, et al. Recomendaciones para el diagnóstico y tratamiento de la fibrosis pulmonar idiopática. Guía ALAT 2014.
- Maher T. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med. 2012;33:69–83.
- Ahluwalia N, Shea B, Tager. New therapeutic targets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(8):867–78.
- Stuebner M, Christine D, Garcia K. Genetic interstitial lung disease. Clin Chest Med. 2012;33:95–110.
- Demedts M, Behr J, Buhl R, et al. High dose acetylcistein in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353;2229-42.
- The idiopathic pulmonary fibrosis clinical research network. Prednisone, azatioprine, and -acetylcistein for pulmonary fibrosis. N Engl J Med. 2012;366;1968-77.
- Raghu G, Anstron J, King T, et al. Randomized trial of acetylcisteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014.
- Raghu G, Rochwerg B, Zhang Y. et al. An official ATS/ERS/JRS/ALAT Clinical Practice guideline: treatment of idiopathic pulmonary fibrosis: Executive Summary. Am J Respir Crit Care Med. 2015; 192:238-48.
- Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-9.
- Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet. 2011:377:1760-9.
- King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med.
- ;370:2083–92.
- Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinasa inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-87.
- Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.
- Xaubet A, Ancochea J, Bollo E et al. Normativa sobre el diagnóstico y tratamiento de la fibrosis pulmonar idiopática. Arch Bronconeumol. 2013;49(8):343-53.
- Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis;a disease with similarities and links to cancer biology. Eur Respir J. 2010;35:496-504.
- Raghu G, Collard H, Amstrom K. Idiopathic pulmonary fibrosis. Clinically meaningful primary endpoints in phase 3 clinical trials. Am JRespir Crit Care Med. 2012;185(10): 1044-8.
Information
Journal history
Keywords
QR code
Funding
Support + Info: Here
Directories and indexes
Google Scholar profile
Most read in the last 30 days
